BRPI0518823A2 - compostos de triazol adequados para o tratamento de transtornos que respondam À modulaÇço do receptor d3 da dopamina - Google Patents

compostos de triazol adequados para o tratamento de transtornos que respondam À modulaÇço do receptor d3 da dopamina

Info

Publication number
BRPI0518823A2
BRPI0518823A2 BRPI0518823-7A BRPI0518823A BRPI0518823A2 BR PI0518823 A2 BRPI0518823 A2 BR PI0518823A2 BR PI0518823 A BRPI0518823 A BR PI0518823A BR PI0518823 A2 BRPI0518823 A2 BR PI0518823A2
Authority
BR
Brazil
Prior art keywords
dopamine
fluorinated
alkyl
cycloalkyl
disorders
Prior art date
Application number
BRPI0518823-7A
Other languages
English (en)
Inventor
Andreas Haupt
Wilfried Braje
John Darbyshire
Sean C Turner
Gisela Backfisch
Liliane Unger
Armin Beyerbach
Karla Drescher
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of BRPI0518823A2 publication Critical patent/BRPI0518823A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTOS DE TRIAZOL ADEQUADOS PARA O TRATAMENTO DE TRANSTORNOS QUE RESPONDAM A MODULAÇçO DO RECEPTOR D~ 3~ DA DOPAMINA. A invencão se refere a compostos de fórmula (I) em que n é 1 ou 2, Ar é um radical 1,2,4-triazol ligado a C que possui um radical R¹ no átomo de carbono restante e um radical R^ 1a^ em s átomos de nitrogênio; R¹ é hidrogênio, um do C~ 1~-C~ 6~ alquila, C~ 3~ - C~ 6~ cicloalquila, C~ 1~ - C~ 4~ alcoximetila, C~ 1~ - C~ 6~ alquila fluorada, C~ 3~ - C~ 6~ cicloalquila fluorada, C~ 1~ - C~ 4~ alcoximetila fluorada ou fenila ou heteroarila de 5 ou 6 elementos opcionalmente substituida; R^ 1a^ é hidrogênio ou C~ 1~ - C~ 4~ alquila; e R² e C~ 1~ - C~ 6~ alquila, C~ 3~ - C~ 6~ cicloalquila, C~ 1~ - C~ 6~ alquila fluorada ou C~ 3~ - C~ 6~ cicloalquila fluorada; e aos sais de adição de ácido fisiologicamente tolerados desses compostos. A invenção também se refere a uma composiçâo farmacêutica que compreenda pelo menos um composto de triazol de fórmula (I) e/ou pelo menos um sal de adição de ácido fisiologicamente tolerado dele, e também a um método para o tratamento de transtornos que respondam beneficamente a antagonistas do receptor D~ 3~ de dopamina ou agonistas de D~ 3~ de dopamina, o dito método compreendendo a administração de uma quantidade eficaz de pelo menos um composto de triazol ou sal de adição de ácido fisiologicamente tolerado de fórmula (I) a um sujeito necessitado.
BRPI0518823-7A 2004-12-02 2005-12-01 compostos de triazol adequados para o tratamento de transtornos que respondam À modulaÇço do receptor d3 da dopamina BRPI0518823A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63241204P 2004-12-02 2004-12-02
PCT/EP2005/012856 WO2006058753A1 (en) 2004-12-02 2005-12-01 Triazole compounds suitable for treating disorders that respond to modulaiont of the dopamine d3 receptor

Publications (1)

Publication Number Publication Date
BRPI0518823A2 true BRPI0518823A2 (pt) 2008-12-09

Family

ID=35976712

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518823-7A BRPI0518823A2 (pt) 2004-12-02 2005-12-01 compostos de triazol adequados para o tratamento de transtornos que respondam À modulaÇço do receptor d3 da dopamina

Country Status (14)

Country Link
US (2) US8101754B2 (pt)
EP (1) EP1817037B1 (pt)
JP (1) JP5049134B2 (pt)
KR (1) KR20070106989A (pt)
CN (1) CN101384263A (pt)
AU (1) AU2005311452A1 (pt)
BR (1) BRPI0518823A2 (pt)
CA (1) CA2588457A1 (pt)
ES (1) ES2417488T3 (pt)
IL (1) IL183542A0 (pt)
MX (1) MX2007006598A (pt)
TW (1) TW200633710A (pt)
WO (1) WO2006058753A1 (pt)
ZA (1) ZA200705008B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040204422A1 (en) 2003-04-14 2004-10-14 Abbott Gmbh & Co. Kg. N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
DE602005018366D1 (de) * 2004-08-09 2010-01-28 Abbott Gmbh & Co Kg Zur behandlung von auf eine modulation des dopamin-d3-rezeptors ansprechende erkrankungen geeignete 4-piperazinylpyrimidinverbindungen
CN101384263A (zh) * 2004-12-02 2009-03-11 艾博特股份有限两合公司 适合治疗对多巴胺d3受体调节产生反应的疾病的三唑化合物
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
US7935706B2 (en) 2006-02-23 2011-05-03 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
CN103497114A (zh) * 2007-06-29 2014-01-08 埃莫里大学 用于神经保护的nmda受体拮抗剂
PA8802101A1 (es) * 2007-11-02 2009-08-26 Abbott Gmbh & Co Kg Compuestos de 1,2,4-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina d3

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4425144A1 (de) * 1994-07-15 1996-01-18 Basf Ag Triazolverbindungen und deren Verwendung
US6403593B1 (en) * 1995-07-14 2002-06-11 Abbott Laboratories Triazole compounds and the use thereof
DE19728996A1 (de) * 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
AR022228A1 (es) 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para la preparar dicha composicion
GB0212399D0 (en) * 2002-05-29 2002-07-10 Glaxo Group Ltd Compounds
TW200510395A (en) * 2003-06-05 2005-03-16 Abbott Gmbh & Co Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
US6919342B2 (en) * 2003-06-05 2005-07-19 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
CA2570501A1 (en) 2004-06-18 2006-01-26 Gergely Szakacs Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
CN101384263A (zh) * 2004-12-02 2009-03-11 艾博特股份有限两合公司 适合治疗对多巴胺d3受体调节产生反应的疾病的三唑化合物

Also Published As

Publication number Publication date
ES2417488T3 (es) 2013-08-08
WO2006058753A1 (en) 2006-06-08
US8101754B2 (en) 2012-01-24
AU2005311452A1 (en) 2006-06-08
US20080171751A1 (en) 2008-07-17
MX2007006598A (es) 2007-09-21
CN101384263A (zh) 2009-03-11
JP5049134B2 (ja) 2012-10-17
IL183542A0 (en) 2007-09-20
ZA200705008B (en) 2008-09-25
JP2008521859A (ja) 2008-06-26
US20120095015A1 (en) 2012-04-19
CA2588457A1 (en) 2006-06-08
EP1817037B1 (en) 2013-04-03
EP1817037A1 (en) 2007-08-15
TW200633710A (en) 2006-10-01
KR20070106989A (ko) 2007-11-06

Similar Documents

Publication Publication Date Title
BRPI0518823A2 (pt) compostos de triazol adequados para o tratamento de transtornos que respondam À modulaÇço do receptor d3 da dopamina
RU2500673C2 (ru) Гетероциклические ингибиторы мек и способы их применения
MX2023007192A (es) Inhibidores de prmt5.
MY149038A (en) Cinnamide compound
MX2022010011A (es) Inhibidores de prmt5 novedosos.
BRPI0408784A (pt) método para usar um composto
DE60022366T2 (de) Kondensierte imidazolderivate und arzneimittel gegen diabetes mellitus
BRPI0705235A2 (pt) composiÇço agroquÍmica e mÉtodo de fabricaÇço e uso da mesma
MX2022007105A (es) Formas solidas de sal de 1,3-dihidroxi-2-(hidroximetil)propan-2-am ina de acido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1, 3] dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il) metil)-1h- benzo[d]imidazol-6-carboxilico.
MA32428B1 (fr) Composition fongicide et procede pour lutter contre des maladies de plantes
MX2022008626A (es) Triazinonas sustituidas como agonistas del receptor de la hormona tiroidea.
ES2149777T3 (es) Derivados de triazol que tienen actividad antifungica.
MX2021015325A (es) Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa.
WO2008129966A1 (ja) 有害生物防除組成物
ZA200711080B (en) 1-(2-amino-3-(substituted alkyl)-3H-benzimidazoilymethyl)-3-substituted-1,3-dihydro-benzoimidazol-2-ones with activity on respiratory syncytial virus
BRPI0516529A (pt) compostos de 6-amino(aza)indano apropriados para o tratamento de distúrbios que respondem à modulação do receptor de dopamina d3
ATE257825T1 (de) Benzimidazol-verbindungen
MY144623A (en) Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht 1f agonists
NO20072418L (no) Arylsulfonylmetyl- eller arylsufonamidsubstituerte aromatiske forbindelser egnet for behandling av lidelser som reagerer pa modulering av dopamin D3-reseptoren
UA99634C2 (ru) Производные 1,2,4,-триазин-3,5-диона для лечения нарушений, реагирующих на модулирование рецептора допамина d3
BR112021006424A2 (pt) inibidores de quinase tyk2
AU1316892A (en) Use of 4-amino-1-(2-pyridyl)piperidines for the preparation of a medicament for the treatment and prophylaxis of conditions deriving from disorders of the serotoninergic systems mediated by 5-ht3 receptors
TW200510395A (en) Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
HUP0004330A2 (hu) Szinergetikus fungicid hatóanyag-keverék amidvegyületek és benzimidazolok vagy ezeket leadó elővegyületek alapján és alkalmazása
NO20034252D0 (no) Halogensubstituerte kinolinderivater og middel for kontroll av ektoparasitter

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.